A U.S. court decision has significantly limited mail-order access to mifepristone, a key medication used in abortions. This ruling restricts the availability of the drug, which currently represents the most common method for abortion procedures across the United States. The move is expected to have widespread implications for reproductive healthcare access.

The court decision curbs access to the drug used in medication abortions, which is currently the most common method for the procedure in the US.